Catalog No.
DHC18801
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Mouse
Isotype
IgG1-nd
Clonality
Monoclonal
Target
Lymphocyte antigen T1/Leu-1, CD5, T-cell surface glycoprotein CD5, LEU1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P06127
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
H65-ricin A chain immunotoxin, H65-RTA
Clone ID
Zolimomab
Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation, PMID: 8258255
Toxicologic evaluations of an immunotoxin, H65-RTA, PMID: 7657064
XomaZyme-791 and XomaZyme-H65, PMID: 2620256
Application considered for immunotoxin in treatment of graft-vs-host disease, PMID: 2013915
A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus, PMID: 7532717
Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation, PMID: 7584486
Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant, PMID: 8607177
A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts, PMID: 2650413
Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant., PMID:8607177
Toxicologic evaluations of an immunotoxin, H65-RTA., PMID:7657064
A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus., PMID:7532717
Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation., PMID:7584486
Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation., PMID:8258255
Application considered for immunotoxin in treatment of graft-vs-host disease., PMID:2013915
A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts., PMID:2650413
XomaZyme-791 and XomaZyme-H65., PMID:2620256
For research use only. Not for human or drug use.
